PsychoGenics’ High Data Security Standards Are Certified by The NIH
PsychoGenics Inc. (PGI), a provider of AI-based phenotypic platforms and preclinical assays for the development of therapeutics for pain, neurodegenerative,...
Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia
May 10, 2019 – Marlborough, Mass., and Paramus, N.J., – Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today announced...
Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia
September 27, 2019 – Marlborough, Mass., and Paramus, N.J. , – Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today...
Gary Wartenberg, M.S.
Gary has over 35 years of experience in the field of laboratory animal science and management, spanning pharmaceutical, academia, and...
We Need a New Prozac: The Demand for Brain Drug Innovation
[et_pb_section fb_built=”1″ _builder_version=”4.17.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.17.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title meta=”off” featured_image=”off” _builder_version=”4.17.6″ _module_preset=”default” global_colors_info=”{}”][/et_pb_post_title][et_pb_text _builder_version=”4.17.6″ _module_preset=”default” global_colors_info=”{}”]...
Industrializing Behavioral Testing to Redefine Neuropsychiatric Drug Discovery
PsychoGenics uses a high-throughput platform comprising cameras and AI to analyze the behaviors of mice given a drug candidate before...
Mental Health Champions: Why & How Dr. Emer Leahy of PsychoGenics Is Helping To Champion Mental Wellness
By Yitzi Weiner · Aug. 14, 2022 · Medium Delegate and accept imperfection — I find myself getting anxious when...
Measurement of brain microglial proliferation rates in vivo in response to neuroinflammatory stimuli: application to drug discovery.
Shankaran, M.; Marino, M. E.; Busch, R.; Keim, C.; King, C.; Lee, J.; Killion, S.; Awada, M.; Hellerstein, M. K....
Application of triple-probe microdialysis for fast PK/PD evaluation of dopamimetic activity of drug candidates in the rat brain.
Weikop, P.; Egestad, B.; Kehr, J. J Neurosci Methods 2004, 140, 59-65.
Culture
Teamwork. Excellence. Creativity. Entrepreneurial spirit. At PsychoGenics, we love what we do. We care deeply about making a meaningful difference...